Karen Carey

ImClone Beginning Erbitux Lung Cancer Phase III Work

Oct. 11, 2004

Eight months after receiving approval for Erbitux in colorectal cancer, ImClone Systems Inc. and Bristol-Myers Squibb Co. set out on another Phase III program for the drug, this time targeting non-small-cell lung cancer. (BioWorld Today)

rAAT Phase II Study Misses In Atopic Dermatitis; ProMetic Falls

Oct. 8, 2004

By Karen Carey

Theravance Prices $98M IPO; Three Others Raise $85M Total

Oct. 8, 2004

By Karen Carey

The first full week of October proved to be a busy one for financings in the biotechnology world. (BioWorld Today)

Merck Gains Broader License To Norak's Transfluor Technology

Oct. 7, 2004

By Karen Carey

Genelabs Falls 65 Percent On Failed Prestara Trial In Lupus

Oct. 6, 2004

By Karen Carey

Affymax Begins Clinical Trials With Anemia Product Hematide

Oct. 5, 2004

By Karen Carey

MedImmune Licenses TIRC7 Compound From GenPat77

Oct. 4, 2004

By Karen Carey

Vicuron Sells Shares, Gets $70.8M For Lead Products

Oct. 1, 2004

By Karen Carey

As it prepares regulatory filings for anidulafungin and dalbavancin, Vicuron Pharmaceuticals Inc. priced a public offering worth $70.8 million in gross proceeds. (BioWorld Today)